Table 1.
Comparison of L1 VLP and L1-L2 VLP seroassays with PsV neutralization assays for measurement of HPV16 and -18 antibodies (n = 259)
| HPV seroassay resulta | No. of HPV PsV neutralization assay samplesb: |
Overall agreement (%) | κ (95% CI) | |
|---|---|---|---|---|
| Positive | Negative | |||
| HPV16 antibody | ||||
| HPV L1 VLP seroassay | ||||
| Positive | 29 | 24 | 89 | 0.60 (0.48–0.73) |
| Negative | 5 | 201 | ||
| HPV L1-L2 VLP seroassay | ||||
| Positive | 30 | 25 | 89 | 0.61 (0.49–0.74) |
| Negative | 4 | 200 | ||
| HPV18 antibody | ||||
| HPV L1 VLP seroassay | ||||
| Positive | 13 | 23 | 89 | 0.43 (0.26–0.60) |
| Negative | 5 | 218 | ||
| HPV L1-L2 VLP seroassay | ||||
| Positive | 12 | 2 | 97 | 0.74 (0.56–0.91) |
| Negative | 6 | 239 | ||
a
Multiplex assay for HPV16 and -18.
b
Separate assays were performed for HPV16 and -18.